Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$76,178.00-0.96%ETH$2,419.58-2.27%GOLD$4,388.30+1.28%OIL$103.42-2.28%
Smart Investors Daily
CytomX Therapeutics, Inc. logo

NASDAQ · CTMX

CytomX Therapeutics, Inc.

Healthcare · Biotechnology

$2.69

Down-$0.51 (-15.94%)

Updated Sep 16, 2026, 4:31 AM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
686.8M
P/E ratio
23.88
Dividend yield
0.00%
52-week range
$2.82 – $8.21
Volume
7.51M
Avg. volume
3.54M

Price performance

CTMX price history

1M range · 20 trading sessions · Daily adjusted prices

CTMX closed at $2.69 after 20 trading sessions, down 20.65% for the selected period.

Last close
$2.69
Period change
-20.65%
Period low
$2.69
Period high
$3.72
Daily close
View OHLC price history
CTMX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$3.20$3.205$2.665$2.697.51M
Sep 14, 2026$3.335$3.36$3.145$3.206.14M
Sep 11, 2026$3.38$3.406$3.23$3.292.25M
Sep 10, 2026$3.50$3.52$3.335$3.352.06M
Sep 9, 2026$3.66$3.66$3.495$3.542.05M
Sep 8, 2026$3.612$3.66$3.58$3.651.98M
Sep 4, 2026$3.64$3.725$3.53$3.712.3M
Sep 3, 2026$3.73$3.82$3.61$3.682.56M
Sep 2, 2026$3.72$3.885$3.69$3.726.5M
Sep 1, 2026$3.32$3.73$3.32$3.678.82M
Aug 31, 2026$3.20$3.375$3.17$3.362.38M
Aug 28, 2026$3.40$3.42$3.21$3.212.17M
Aug 27, 2026$3.455$3.52$3.285$3.422.58M
Aug 26, 2026$3.35$3.38$3.285$3.322.22M
Aug 25, 2026$3.32$3.445$3.32$3.374.03M
Aug 24, 2026$3.30$3.38$3.175$3.293.19M
Aug 21, 2026$3.31$3.415$3.27$3.282.89M
Aug 20, 2026$3.53$3.5599$3.27$3.292.61M
Aug 19, 2026$3.48$3.60$3.46$3.574.58M
Aug 18, 2026$3.41$3.4346$3.30$3.392.46M

Latest CTMX news

The latest Smart Investors Daily articles mentioning CTMX.

Stock researchCompany · Overview

CTMX research

Overview

Company profile and research snapshot.

Company profile

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$6.50
Implied upside
—
Analysts
14
CTMX recent ratings
DateFirmRatingTarget
Aug 13, 2026JP MorganOverweight—
Aug 10, 2026GuggenheimBuy—
May 11, 2026HC Wainwright & Co.Buy—
Mar 23, 2026Piper SandlerOverweight—
Mar 19, 2026BarclaysOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 1, 2026

CytomX Therapeutics to Present at Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September. Wells Fargo 21st Annual Healthcare ConferenceDate: Tuesday, September 8, 2026 Fireside Chat: 2:15 p.m. ETLocation: Boston, MA 2026 Cantor Global Healthcare ConferenceDate: Wednesday, September 9, 2026Fireside Chat: 10:20 a.m.

Yahoo · Aug 27, 2026

CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)

- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in 1H 2027 - SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Varseta-M fo

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By